
Continuous glucose monitors: should people who don't live with diabetes be wearing them?
A video Gwyneth Paltrow posted on Instagram in May starts with the actor turned wellness influencer stretching with a CGM conspicuously on her arm before she proceeds to make grain-free almond and coconut pancakes with a strawberry compote. Many in the comments questioned her use of a CGM, with some saying she risked stoking a 'dangerous trend' given many diabetes sufferers struggle to get access to them.
Other influencers have directly promoted CGMs to people who don't live with diabetes, claiming it can help people manage their metabolism, and thereby improve energy, mood and sleep. Dr Fiona Willer, the president of Dietitians Australia, worries about the proliferation of the devices and questions whether some people may have 'fallen down a wellness rabbit hole'.
Glucose, the sugar in our blood, is 'there to help fuel all of our cells – our muscle cells, brain cells, all of them – and so we do need sugar in our blood, it's a bit like the petrol in a car,' Willer says.
'Any form of carbohydrate that we eat, whether that's lollies or whole grain bread, is turned into glucose, which makes its way into our bloodstream.' The body can also recycle glucose from the stored energy of food we've already eaten, Willer says.
Those with diabetes need to monitor their glucose levels because their bodies have trouble making or using insulin – the hormone created by the pancreas that helps move glucose from our bloodstream into the body's cells to make energy.
The blood glucose of people who don't have regulation issues still fluctuates across the day, going up and down depending on what we eat, physical activity level, as well as things like whether we're ill or going through puberty, Willer says. 'For people who don't have diabetes, that fluctuation will occur within a tighter range, while for people who do have diabetes, their blood glucose levels stray outside of what we would call the reference range.'
People with diabetes previously had to use a finger prick test to measure their blood glucose levels. The CGM is a relatively new device that uses a sensor to measure glucose via the fluid between cells every few minutes and then sends the reading to a receiver or smartphone app. For people with diabetes, the reading can then help them manage their glucose levels by influencing how they eat or using some glucose-modifying drugs like insulin.
Clinical endocrinologist Prof Jenny Gunton says CGMs can 'hugely improve the quality of life' for people living with type 1 diabetes, as well as pregnant women who have gestational diabetes and people with type 2 diabetes on insulin.
Gunton, who heads the Centre for Diabetes, Obesity and Endocrinology Research at the Westmead Institute for Medical Research, says that outside of these groups, wearing a CGM can be useful to understand blood glucose levels after various foods and exercise, but warns that 'like any device that gives lots of information, CGMs can sometimes increase anxiety and stress'.
They are also expensive. For people who aren't eligible for a government subsidy, it can cost more than $100 for a sensor that lasts just 14 days.
A study led by the University of the Sunshine Coast in 2022 found CGMs provide little benefit for healthy athletes without diabetes. Separately, researchers who analysed the available evidence of the utility of CMGs among people not living with diabetes in 2024 said that due to the lack of evidence, 'we urge for the commercial claims suggesting the utility of the device in [this population] to be labelled as misleading'.
Willer welcomes people trying to understand how their body works, but says any idea of a 'magic number' for glucose levels for someone who doesn't have insulin resistance or diabetes is 'completely imaginary'. She also says it could lead people to becoming unnecessarily restrictive with their diet and trying to control their body in a way that is not necessarily healthy.
'It's a bit like calorie counting, in that it's one metric that can give people the impression that it kind of wraps everything up together, that it is an indicator for everything. But just like calorie counting, it is actually hugely reductionistic, and it means that we lose so much context about why we eat, when we eat, the sorts of things we eat, and how food functions in our social and cultural experiences as well.'
Willer recommends for people who are interested in living a healthier lifestyle and want an individual approach to speak to a health expert rather than buy a product online.
'Even if they have purchased a CGM, a dietitian or another health professional will help understand, to help them interpret what's going on with their numbers against their actual behaviours.'
Natasha May is Guardian Australia's health reporter
Antiviral is a fortnightly column that interrogates the evidence behind the health headlines and factchecks popular wellness claims
What health trend do you want examined?
Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian.
Your contact details are helpful so we can contact you for more information. They will only be seen by the Guardian.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
an hour ago
- The Independent
Millions of diabetes patients could be given weight loss jabs sooner
New draft guidance from Nice proposes a significant overhaul of type 2 diabetes care in England, moving towards personalised treatment to prevent serious complications. SGLT-2 inhibitors, which protect the heart and kidneys, are recommended as a first-line treatment option, potentially saving nearly 22,000 lives. The guidelines aim to address the current under-prescription of SGLT-2 inhibitors, particularly among women, older people, and black patients, to reduce health inequalities. GLP-1 receptor agonists, including semaglutide, are also suggested for earlier use in some patients, alongside tailored recommendations for specific conditions. This shift represents a holistic approach to type 2 diabetes management, focusing on cardiovascular and kidney health, and is open for public consultation until 2 October.


Telegraph
2 hours ago
- Telegraph
NHS relaxes rules on weight-loss jabs for millions of diabetes patients
Millions more NHS patients could be offered Ozempic or Mounjaro in the biggest overhaul in diabetes treatment for a decade. The National Institute of Health and Care Excellence (Nice), the NHS medicines watchdog, has issued new draft guidance calling for the use of GLP-1 jabs, first developed for diabetes but now widely used for weight loss, to be ramped up significantly. It means the majority of people in Britain with type 2 diabetes – around five million in total – could be given the drugs to help prevent further illnesses. Experts hailed the proposed guidance as 'propelling treatment into the 21st century'. Prof Jonathan Benger, the deputy chief executive and chief medical officer at Nice, said the changes would mean 'more people will be offered medicines where it is right to do so'. He said: 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health.' He added that by recommending both classes of drug sooner, the NHS 'could help prevent heart attacks, strokes and other serious complications before they occur'. Drugs mimic hormones Under the draft guidance, doctors will be able to give the revolutionary drugs – GLP-1 receptor agonists – to diabetes patients who also have heart disease or are obese. They work by mimicking a hormone that regulates blood sugar and appetite. It has since also been revealed that they could help with a range of conditions such as cancer, heart disease and even dementia. Some 200,000 people are currently taking a GLP-1 injection on the NHS, three quarters of whom are using them for diabetes. The remainder are taking them for weight loss. It is thought as many as 1.3 million people in the UK are on the jabs privately. More than five million people in the UK are living with type 2 diabetes. It develops in adulthood and occurs when not enough of the hormone insulin is produced, leading to a rise in blood sugar levels. The new NHS guidance says the jabs should be considered in diabetes patients who have also been diagnosed with heart disease, heart failure, or have early onset type 2, which means they were diagnosed before age 40. People with both diabetes and obesity – a body mass index (BMI) over 35 – will also be able to get the jabs if they have not had success in bringing down their blood sugar levels within the first three months of using another drug. While there are no public figures on eligibility, millions of patients could fall into the relevant categories. It is common for people with diabetes to also suffer from heart issues and other related conditions, while up to 90 per cent are overweight or obese, with weight being the number one preventable cause of the condition. Diabetes UK estimates 168,000 people have early onset type 2, while the condition also causes about 250,000 heart attacks, strokes or cases of heart failure, each year – the leading cause of death in diabetes patients. Nice said the drugs were 'recommended as much for their cardiovascular benefits as for their glycaemic [blood sugar] benefits'. It estimates that 655,000 people with heart disease could benefit from the drugs, as well as 99,000 with early onset type 2. Nice said the initial rise in costs for the NHS would be offset in the longer term by reducing the need for other, sometimes more complex, treatment later on. It was revealed last week that the price of Mounjaro privately would be more than doubled from Sept 1 to a wholesale price of up to £300. The NHS bracing for an increase in demand and more people are expected to turn to competitor Wegovy. Some diabetes patients will already be eligible for, or taking, weight-loss jabs, on the NHS, but the draft guidance will mean more patients can access the drugs sooner without having to go to a specialist weight management service. To qualify for weight-loss drugs on the NHS, a person must currently have a BMI of over 40 and four related health conditions to receive Mounjaro, or attend a specialist weight management service, where waiting times can be up to a year or longer, with a BMI of over 35 and one related condition, to receive Wegovy. The draft guidance, which is out for consultation until October, also recommends making better use of another 'under-prescribed' class of drugs called SLGT-2 inhibitors. These daily pills include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. They reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. The new guidelines recommend patients who cannot tolerate metformin – the first choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. Drugs could protect heart and kidneys The watchdog said there was new evidence suggesting the drugs protect the heart and kidneys as well as controlling blood sugar, and could save almost 22,000 lives. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'


Daily Mail
3 hours ago
- Daily Mail
Tear-jerking moment 11-year-old calls her father with news she's getting a donor heart after 300 days on waitlist
A young girl from Ohio wasted no time calling her father just seconds after learning she would be receiving a new heart. Ava Cooper, 11, has battled multiple serious heart defects since she was just six days old - including a hole in her heart, a heart positioned on the opposite side of her chest, reversed pumping chambers, and a missing or blocked pulmonary valve, according to the Cleveland Clinic. Despite undergoing multiple open-heart surgeries by the age of five, Ava's health began to rapidly decline in the summer of 2024 - prompting doctors to conclude that a heart transplant was her best chance for survival. After spending nearly 300 days at Cleveland Clinic Children's Hospital, the moment Ava and her family had been waiting for finally arrived - a donor heart had become available. Ava was sitting on her hospital bed, unaware that the life-changing news she was about to receive - and her emotional reaction - was about to be lovingly captured on video. In the clip, Ava appears to be on a video chat with her father when a nurse approaches her bedside, smiling brightly as she leans in to whisper something in her ear. Immediately, Ava's hands flew to her mouth in disbelief, her eyes widening as she quickly scanned the room, searching for confirmation of what she was hearing. 'Daddy,' she said into her iPad, her voice trembling with excitement. 'I'm getting a heart.' Her father, clearly as stunned as Ava, responded, 'What?!' 'I'm getting a heart!' she exclaimed, beaming from ear to ear as someone else in the room let out tears of joy. 'I was so excited and couldn't believe it was actually happening,' Ava told the Cleveland Clinic after hearing the news. Dr. Madeleine Townsend, part of Ava's care team, said she wanted to let Ava be the one to share the news herself. 'I whispered it to Ava because I really wanted her to be the one to tell her parents,' she said. 'Getting to see Ava's smile that day is one of the best parts of my job.' Sean Cooper, Ava's father, shared in the excitement during the call, his voice breaking with emotion as tears welled up upon hearing that his daughter would have a new lease on life. 'The hospital had become our second home, so hearing Ava say those words, "I'm getting a heart," was overwhelming,' Sean told Cleveland Clinic. 'After everything she'd been through, we were finally one step closer to coming home for good.' Ava's health journey began almost from the moment she was born, undergoing her first heart surgery just days after entering the world. 'After she was born, Ava had to be immediately flown to another hospital,' Jamie Cooper, her mother, told the outlet. 'I didn't even get the chance to spend time with her,' she added. Although a total of four open-heart surgeries seemed to stabilize her condition by the time she was five, Ava only remained symptom-free until the summer of last year. 'Ava started getting sick. I was noticing her waking up with facial swelling, not able to lay flat all the way, having a hard time breathing,' Jamie said. 'Her doctors at the time determined she was in heart failure.' It was at this point that Ava was transferred to Cleveland Clinic Children's, where a specialized team - including two pediatric heart function and transplant cardiologists - took over her care. They quickly determined that a heart transplant was the best option, concluding that further surgeries would no longer improve her long-term quality of life. In September 2024, at just 10 years old, Ava was officially placed on the heart transplant waiting list. While in the hospital, her health had its ups and downs - she needed oxygen to breathe, a feeding tube for nutrition, and a Berlin Heart device to help her heart pump blood. 'We had Sunday dinners, threw a birthday party for Ava's sister in her hospital room and even brought up presents to open on Christmas morning. We were still trying to find ways to create memories together,' Jamie recalled. One of Ava's most treasured memories came in February 2025, when hospital staff transformed her room into a special father-daughter dance venue, knowing she would miss the one she usually attends at that time of year. 'It's now one of the best memories I have with Ava, and I'm incredibly grateful to everyone who came together to make it possible,' Sean said. Less than a month after what Ava called her 'magical and cool' father-daughter dance, the hospital received a heart that would soon be hers. On March 6, Ava underwent the transplant surgery and emerged with a brand-new heart. She spent the next month in the hospital recovering. Her doctor explained that because she had been in heart failure for almost a year, her body needed time to heal. 'I was so excited to be back in my own bedroom and be able to see my dog Rocky again,' Ava told Cleveland Clinic. By April 10, Ava was finally able to go home for the first time in months. 'Even though I missed my whole fourth-grade class, I'm excited I'm able to see my friends, go on field trips and do art projects again,' Ava said.